classic
develop
vaccin
lengthi
tediou
may
necessarili
success
demonstr
case
hiv
especi
problem
emerg
pathogen
newli
introduc
human
popul
carri
inher
risk
pandem
spread
popul
situat
consider
number
differ
platform
technolog
develop
also
develop
pathogen
directli
deriv
vaccin
regard
complic
even
danger
due
induct
ineffici
unwant
immun
respons
caus
consider
sideeffect
dengu
viru
among
platform
technolog
plasmidbas
dna
vaccin
rna
replicon
singleround
infecti
vector
particl
replic
vaccinebas
vector
encod
critic
antigen
target
pathogen
among
latter
recombin
measl
virus
deriv
vaccin
strain
test
measl
vaccin
among
effect
safest
lifeattenu
vaccin
known
therefor
develop
schwarz
moraten
aikcstrain
deriv
recombin
vaccin
wide
rang
mostli
viral
also
bacteri
pathogen
quit
straightforward
vaccin
gener
induc
power
humor
cellular
immun
respons
appropri
anim
model
ie
transgen
mice
nonhuman
primat
also
recent
first
clinic
phase
trial
result
quit
encourag
trial
indic
expect
safeti
efficaci
also
human
patient
interestingli
independ
level
preval
antimeasl
immun
trial
therebi
recombin
measl
vaccin
express
addit
antigen
promis
platform
futur
vaccin
abstract
classic
develop
vaccin
lengthi
tediou
may
necessarili
success
demonstr
case
hiv
especi
problem
emerg
pathogen
newli
introduc
human
popul
carri
inher
risk
pandem
spread
popul
situat
consider
number
differ
platform
technolog
develop
also
develop
pathogen
directli
deriv
vaccin
regard
complic
even
danger
due
induct
ineffici
unwant
immun
respons
caus
consider
sideeffect
dengu
viru
among
platform
technolog
plasmidbas
dna
vaccin
rna
replicon
singleround
infecti
vector
particl
replic
vaccinebas
vector
encod
critic
antigen
target
pathogen
among
latter
recombin
measl
virus
deriv
vaccin
strain
test
measl
vaccin
among
effect
safest
lifeattenu
vaccin
known
therefor
develop
schwarz
moraten
aikcstrain
deriv
recombin
vaccin
wide
rang
mostli
viral
also
bacteri
pathogen
quit
straightforward
vaccin
gener
induc
power
humor
cellular
immun
respons
appropri
anim
model
ie
transgen
mice
nonhuman
primat
also
recent
first
clinic
phase
trial
result
quit
encourag
trial
indic
expect
safeti
efficaci
also
human
patient
interestingli
independ
level
preval
antimeasl
immun
trial
therebi
recombin
measl
vaccin
express
addit
antigen
promis
platform
futur
vaccin
keyword
measl
viru
lifeattenu
vector
revers
genet
emerg
infect
vector
platform
measl
scourg
mankind
sinc
year
account
million
death
year
histor
time
due
extrem
high
transmiss
rate
r
diseas
spread
like
wildfir
among
popul
usual
childhood
diseas
pathogen
wildtyp
measl
viru
mv
induc
transient
albeit
pronounc
immun
suppress
infect
patient
render
suscept
secondari
infect
especi
low
hygien
condit
one
caus
consider
mortal
rate
measl
lowdevelop
countri
nevertheless
even
industri
countri
mortal
rate
infect
preval
due
direct
effect
mv
infect
neurolog
complic
ie
primari
measl
enceph
acut
dissemin
encephalomyel
adem
mv
inclusionbodi
enceph
mibe
subacut
sclerot
panenceph
sspe
concur
increas
fatal
rate
therefor
avail
first
effect
safe
measl
vaccin
author
fda
bless
mankind
first
vaccin
deriv
primari
pathogen
wildtyp
viru
isol
boy
name
david
edmonston
viru
isol
edit
anja
ehrhardt
florian
kreppel
michaelmuehlebach
peid
passag
mani
time
differ
primari
cell
cell
line
total
number
passag
human
passag
chicken
cell
yield
attenu
strain
name
edmonston
seed
b
proof
attenu
macaqu
protect
infect
pathogen
strain
also
human
children
vaccin
earli
possibl
matern
antibodi
gone
vaccin
show
efficaci
protect
measl
albeit
signific
number
children
becam
febril
immun
therefor
vaccin
strain
passag
anoth
time
chicken
embryon
fibroblast
includ
passag
reduc
temperatur
give
rise
even
attenu
vaccin
strain
moraten
vaccin
strain
deriv
edmonston
lineag
compar
passag
histori
schwarz
edmonstonzagreb
aikc
edmonstonlineag
vaccin
strain
licens
vaccin
us
eu
japan
confer
high
efficaci
accompani
remark
safeti
profil
inde
measl
vaccin
even
recommend
otherwis
compromis
collect
hivinfect
patient
long
immun
suppress
sever
ie
lymphocyt
count
mm
parallel
lifeattenu
measl
vaccin
strain
eg
leningrad
develop
independ
use
therefor
mv
vaccin
strain
regard
term
safeti
efficaci
ideal
vector
platform
build
recombin
vaccin
present
antigen
choic
immun
system
extrem
immunestimulatori
context
use
chosen
vaccin
vector
platform
technolog
avail
allow
genet
modif
vector
platform
antigen
choic
addit
express
present
recombin
vaccin
mv
belong
order
mononegaviral
famili
paramyxovirida
prototyp
morbillivirus
mv
genom
nonseg
singlestrand
linear
rna
total
length
nucleotid
neg
sens
orient
ssrna
differ
gene
arrang
singl
cassett
call
transcript
unit
genom
structur
especi
negativesens
orient
rna
mononegaviral
genom
render
transcript
viral
mrna
replic
viru
genom
critic
depend
virusencod
ribonucleoprotein
complex
rnp
consist
rna
genom
complex
nucleocapsid
protein
n
phosphoprotein
p
rnadepend
rnapolymeras
rdrp
call
larg
protein
l
therefor
gener
recombin
mononegaviral
biotechnolog
modifi
plasmid
becom
complex
sinc
rna
genom
also
protein
compon
viral
rnp
simultan
present
singl
cell
yield
replic
center
releas
recombin
infecti
viru
process
even
complic
socal
ruleofsix
viral
nucleocapsid
protein
n
tightli
cover
viral
rna
nrna
complex
templat
viral
genom
transcript
replic
howev
genom
whose
nucleotid
number
multipli
six
observ
natur
occur
paramyxovirida
give
rise
respect
recombin
virus
impli
one
hand
modif
virus
genom
take
basic
rule
account
also
transcript
start
stop
recombin
plasmidencod
rna
genom
spot
purpos
polymerasedriven
express
system
viral
rnpcomplex
protein
ie
n
p
l
well
viral
rna
antigenom
set
latter
addit
flank
hepat
delta
viru
ribozym
respect
ensur
correct
length
system
first
establish
rabi
viru
allow
gener
socal
rescu
replic
rabi
viru
plasmid
dna
gener
recombin
mv
edmonston
b
vaccinederiv
laboratori
strain
chosen
passag
multipl
time
vero
cell
complet
viru
genom
engin
encod
addit
tag
sequenc
clone
pbluescript
plasmid
backbon
control
promot
flank
hepat
viru
dribozym
plasmid
could
use
cotransfect
togeth
also
express
plasmid
encod
mv
polymeras
helper
cell
line
express
polymeras
well
mv
n
p
protein
fig
rescu
infecti
replic
recombin
mv
altern
use
stabli
transfect
cell
line
system
use
plasmid
encod
mv
genom
well
express
mv
n
p
l
protein
use
togeth
replicationdefici
vector
fig
rescu
infecti
mv
final
shown
recombin
mv
gener
effici
use
express
plasmid
mv
genom
well
rnp
protein
driven
poliidepend
cmviepromot
fig
rescu
mv
correct
genom
length
due
avail
revers
genet
system
mv
respect
genom
subsequ
modifi
essenti
duplic
critic
stretch
intergen
region
l
h
p
gene
cassett
intergen
region
highli
conserv
contain
stopstart
signal
sequenc
recogn
viral
polymeras
complex
mrna
transcript
therebi
transcript
singular
viral
mrna
realiz
duplic
region
addit
stopstart
signal
introduc
genom
give
rise
stopstartstopstart
signal
sequenc
pattern
therebi
addit
transcript
unit
atu
introduc
use
express
addit
cargo
gene
introduc
respect
orf
first
startsign
render
possibl
mark
recombin
mv
gene
encod
marker
protein
gfp
luciferas
allow
track
viru
principl
gene
may
encod
given
interfer
viral
replic
term
payload
recombin
mv
gener
encod
three
addit
gene
total
extra
size
kb
therebi
expand
genom
size
nearli
factor
usual
recombin
mv
extra
gene
cassett
reveal
replic
properti
similar
parent
empti
mv
kinet
titer
sometim
replic
may
impair
relat
length
also
posit
biolog
encod
protein
gener
extra
gene
next
end
may
larger
impact
replic
extra
cytoplasm
protein
less
problemat
protein
target
via
endoplasm
reticulum
cell
membran
secret
variabl
genom
size
attribut
helic
structur
rnp
complex
easili
expand
addit
extra
n
protein
residu
tandem
pleomorph
particl
structur
allow
packag
larger
rnp
complex
latter
impress
visual
demonstr
copackag
least
two
genom
mv
particl
thu
recombin
mv
allow
insert
quit
larg
addit
code
sequenc
gener
without
lose
effici
replic
capac
encod
gene
first
becom
introduc
mv
genom
realiz
soon
mv
use
vector
express
present
pathogen
critic
antigen
immun
system
context
highli
immunogen
mv
replic
first
hepat
b
viru
surfac
core
antigen
chosen
express
recombin
mv
via
atu
follow
p
gene
cassett
recombin
virus
shown
express
desir
addit
antigen
hbsagencod
mv
provok
signific
humor
antigenspecif
immun
respons
transgen
mvsuscept
ifnar
mous
model
take
optim
advantag
vector
platform
also
respect
regulatori
issu
mv
genom
clone
ident
author
mv
vaccin
strain
today
genom
encompass
exact
sequenc
vaccin
strain
schwarz
moraten
edmonstonzagreb
mvbv
aikc
avail
gener
recombin
platformbas
vaccin
basi
varieti
recombin
mv
gener
mostli
target
viral
pathogen
also
bacteri
antigen
name
helicobact
pylori
fig
schemat
depict
differ
mv
rescu
system
avail
gener
infecti
mv
particl
exact
fulllength
rna
genom
antigenom
simultan
avail
given
cell
togeth
viral
ribonucleoprotein
complex
protein
n
p
l
purpos
genom
origin
driven
polymeras
end
delta
ribozym
yield
need
coexpress
polymeras
addit
purpos
rescu
cell
stabli
express
mvn
mvp
polymeras
cotransfect
mv
genom
plasmid
interest
eg
p
mv
polymerasedriven
express
plasmid
mvl
eg
pemcla
b
altern
express
plasmid
mv
genom
well
compon
rnp
cotransfect
eg
cell
superinfect
replicationdefici
vaccinia
vector
eg
c
final
success
rescu
demonstr
cotransfect
dna
polymeras
ii
driven
express
plasmid
mv
genom
well
compon
rnp
complex
hatch
box
promot
sequenc
dark
gray
box
terminationpolyadenyl
signal
white
box
individu
gene
viru
gene
induc
signific
immun
express
mv
platform
tabl
depict
tabl
recombin
mvderiv
vaccin
test
avail
mous
model
ifnar
transgen
mice
type
interferon
receptor
defici
express
human
homologu
mv
vaccin
strain
receptor
transgen
human
tissu
specif
analyz
recombin
vaccin
induct
signific
humor
immun
respons
found
howev
effect
vaccin
may
necessarili
addit
antigen
encod
upfront
mv
genom
may
determin
empir
test
differ
posit
atu
respect
antigen
exampl
merss
express
higher
encod
h
rather
p
cassett
furthermor
also
power
cellular
immun
respons
trigger
mvderiv
vaccin
addit
encod
antigen
induct
antigenspecif
cell
respons
demonstr
coupl
mvencod
antigen
includ
env
wnve
merss
protect
capac
respons
demonstr
first
wnvvaccin
immun
mice
surviv
otherwis
lethal
challeng
wnv
meanwhil
protect
respect
recombin
vaccin
demonstr
number
mvbase
vaccin
tabl
mous
data
may
challeng
due
knockout
ifnar
necessari
allow
basic
replic
mv
receptortransgen
mice
mvbase
vaccin
progress
nonhuman
primat
nhp
model
altern
transgen
mice
besid
cotton
rat
use
character
vaccin
due
lack
speci
mv
suscept
also
nhp
cotton
rat
recombin
mv
encod
foreign
antigen
remain
immunogen
induc
immun
respons
latter
tabl
base
data
mvchikv
vaccin
schwarzstrain
mv
encod
chikv
vlp
hivenvelop
glycoprotein
respect
progress
phase
clinic
trial
hivvaccin
trial
data
avail
yet
chikvvaccin
trial
gave
interest
insight
efficaci
mvderiv
vaccin
man
cohort
patient
vaccin
dose
infecti
particl
booster
immun
dose
level
day
first
shot
vaccin
induc
immun
respons
volunt
two
shot
high
dose
group
even
without
booster
immun
even
import
studi
reveal
expect
excel
safeti
profil
seriou
sever
solicit
advers
event
headach
local
erythema
local
indur
local
pain
pyrexia
record
among
particip
interestingli
strength
antibodi
respons
host
individu
patient
independ
preform
antimeasl
immun
due
previou
measl
infect
vaccin
demonstr
stratifi
patient
cohort
preval
mvneutral
abrespons
trial
analyz
induc
chikvimmun
thu
clinic
trial
data
respect
impact
preform
antimeasl
immun
accord
result
preclin
anim
model
avail
preclin
data
also
suggest
minor
impact
antimeasl
immun
efficaci
recombin
vaccin
use
mv
platform
technolog
therebi
recombin
mv
vaccin
platformderiv
vaccin
also
suit
patient
alreadi
acquir
antimeasl
immun
preform
antimeasl
immun
expect
therefor
consider
efficaci
despit
immun
regard
quit
import
sinc
antivector
immun
consid
associ
unwant
effect
efficaci
adenovirusderiv
vector
gutless
adenoviru
vector
system
especi
poxviru
vector
mva
could
harbor
larger
genet
insert
recombin
mv
nevertheless
kb
extra
cargo
allow
even
separ
express
cassett
mv
suffici
antigen
moreov
recombin
adenovirusbas
vaccin
candid
alreadi
progress
phase
iii
clinic
trial
total
much
clinic
experi
mv
vaccin
backbon
consid
billion
dose
measl
vaccin
use
yet
look
mv
vaccin
platform
current
avail
vaccin
platform
mva
poxvirus
adenovirus
gener
direct
sidebysid
comparison
especi
consid
efficaci
yet
done
like
effect
compar
vector
end
also
depend
natur
antigen
express
well
immun
respons
requir
protect
due
advent
revers
genet
system
gener
recombin
vaccinestrainderiv
measl
virus
becam
possibl
use
vector
stimul
effect
humor
cellular
immun
respons
pathogen
includ
emerg
infect
vector
vaccin
prove
effect
whole
rang
viral
also
bacteri
pathogen
number
anim
model
well
first
clinic
trial
importantli
extraordinari
advantag
safeti
profil
measl
vaccin
also
appli
recombin
platformbas
vaccin
analyz
yet
therefor
recombin
vaccinestrainderiv
measl
virus
belong
set
potenti
vaccin
platform
well
suit
develop
new
urgent
need
vaccin
emerg
infect
diseas
classic
vaccin
develop
deliv
effect
vaccin
yet
futur
clinic
trial
provid
insight
efficaci
characterist
mv
vector
system
ie
immun
trigger
human
patient
protect
extent
shown
anim
model
longev
immun
respons
measl
vaccin
also
found
respons
trigger
addit
antigen
case
promis
data
avail
yet
suggest
vaccin
excel
homebas
modern
vaccin
develop
provid
sharp
weapon
current
futur
challeng
conflict
interest
author
declar
potenti
conflict
interest
author
support
german
center
infect
research
dzif
ttu
